|
|   |
Pharmacia Corp.
| Headquarters location: 100 Rt. 206 N Peapack, NJ 07977 |  | Tel. 908-901-8000 Job offers, investor relations: www.pnu.com |
|
| shareholder | country  % source |
|
| subsidiary | country  % source |
|
|
name  items photo compare the prices |
Shop local, ethical and at the best price on Ethishop ! |
|
|
« ETHICAL » RATING OF PHARMACIA
, group
Pfizer, Inc.
and subsidiaries
[ ?] |
| Human: 1 violation(s) of fundamental human rights |
| Job: 13% of company's jobs cut since 1998 |
| Environment: 5 major pollution(s) |
| Delinquency: 6 act(s) of financial or trade delinquency |
| Tax haven, secret bank account, shell companies: operates in 16 offshore financial center(s) |
| Sales: more than 48 billion(s) dollars/euros in annual sales |
| Net profit: more than 61 billion(s) dollars/euros in cumulated net profit since 1998 |
| Top management: earns 779 times the median income in the United States (32000 US$/year) |
| Influence: 21 act(s) of direct corruption or lobbying |
| Advertising & marketing: 10 dubious practice(s) |
|
|
year name | photo position; compensation source |
| 2000Ando, Goran |  Vice-president; salary: 1.5 million US$; stock-options: 5.4 million US$; |
| 2000Hassan, Fred |  Chief Executive Officer; salary: 3.5 million US$; |
|
year | dubious practice : image source |
|
|
year | employees <> | social impact : country source |
| 2000 | 59000 | |  |
|
year | purpose : intermediary/lobby : institution source |
| 2000 | Limit the legal liability, no price control, no list of preferred drugs, hampers the approval and marketing of generic drugs, no drug imports, no limit to drug advertising… : Pharmaceutical Research and Manufacturers of America : : US government, congress, senate translate | Washington.  |
|
year | financial misdemeanor | sales | income | | | source |
| 2002 |
Accused with fraud and bribery schemes to inflate prices for consumers and government health plans. |
| | | |   | | Financial .  |
| 2002 |
"Induced physicians to purchase its drugs, rather than competitors', by persuading them that the wider `spread' on the defendant's drugs would allow the physicians to receive more money at the expense of the Medicaid program and Medicare beneficiaries." |
| | | |   | | New York T.  |
| 2001 |
| 13.84 | 1.5 | |   | billion US$ |  |
| 2000 |
| 18.14 | 0.72 | |   | billion US$ |  |
|
|
|
|
Also announce a documentary, a book or an article or comment this company profile.
Goal: present the company activities, improve the ethical rating's accuracy, develop an network of observers.